New Frontiers in Personalized Medicine: Cardiovascular Research & Clinical Care
The George Washington University
January 6, 2011
“PMC has organized a superb program with an impressive lineup of speakers and topics. The discussions and exchange of ideas should help catapult individualized cardiovascular medicine forward – which is desperately needed!”
-Eric J. Topol, M.D., Director, Scripps Translational Science Institute and Chief Academic Officer, Scripps Health
Cardiovascular disease remains the number one cause of death in the U.S., and will likely become the number one cause of death globally. At the same time, new understandings of individual variations are increasingly re-shaping our ability to treat various aspects of the disease.
A special report in Nature noted that, after oncology, cardiology holds the most promise in personalizing, and therefore improving, therapies.
In an unprecedented collaboration of the top organizations and voices in the field, the forthcoming conference New Frontiers in Personalized Medicine: Cardiovascular Research and Clinical Care will bring together leaders from academe, industry and government to address the critical issues facing the future of cardiovascular research and clinical care in science, business and policy.
Chaired by Richard Katz, M.D., of the George Washington University and Jay Wohlgemuth, M.D., of Quest Diagnostics Nichols Institute, the event will be held at George Washington University on January 6, 2011. It is supported and/or co-sponsored by the Personalized Medicine Coalition (PMC), American College of Cardiology (ACC), American Medical Association (AMA), National Heart Lung and Blood Institute (NHLBI), and the Cheney Cardiovascular Institute at George Washington University (GWU). A superb group of speakers, noted in the program agenda below, has been assembled for the conference.
At the conference, ACC will release the results of survey research looking at the adoption of personalized medicine and pharmacogenomic concepts and products in cardiovascular practice. The survey will provide new insights into the rate of adoption of personalized medicine among U.S. cardiologists.
NHLBI has released an Executive Summary of the conference, including summaries of the panels and speakers, as well as recommendations:
View the following presentations from the conference:
- Opening Keynote Address-"From Science to Practice": Victor Dzau, M.D., President and CEO, Duke University Health System and Chancellor for Health Affairs, Duke University
- Ben Salisbury, Ph.D., Vice President, Clinical Genetics, PGxHealth Topic: Long QT Syndrome
Panel Discussion: Shaping the Future of Cardiovascular Care: Emerging Technologies and Needed Evidence Part I: Emerging Technologies
- Moderator: Geoffrey Ginsburg, M.D., Ph.D., Director, Center for Genomic Medicine, Institute for Genome Sciences and Policy, Duke University
- Timothy McCaffrey, Ph.D., Professor of Medicine and Director, Division of Genomic Medicine, The George Washington University Topic: Deep Sequencing: The Next Frontier in Genomic Analysis
- Michael McKenna, Ph.D., Chief Scientific Officer, Tethys Bioscience Topic: Building Effective Risk Stratification Tools and Bringing Them to Market
- H. Robert Superko, M.D., Vice President and Chief of Medical Affairs, Celera Genomics Group Topic: Applying Polymerase Chain Reaction Technology to the Diagnostic, Research, and Forensic Fields
- Jennifer Van Eyk, Ph.D., Director, The Johns Hopkins NHLBI Proteomics Center Topic: Genomics and Proteomics in Cardiovascular Disease
- Jack Lewin, M.D., CEO, American College of Cardiology, Keynote: Genetics, Your Heart and Your Future
- Panel Discussion: Shaping the Future of Cardiovascular Care: Emerging Technologies and Needed Evidence Part II: Emerging Diagnostics and Treatments
- Panel Discussion: Clinical and Regulatory Barriers to Personalized Cardiovascular Care
- Susan Shurin, M.D., Acting Director, NHLBI, Keynote: Cardiovascular Genomic Medicine: Time for a Systems Approach
For more information, contact Gwen Gordon, Communications Director